Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
Proposed rule will revisit controversial provisions in the January 340B final rule to address manufacturer concerns about the US discount program.
Energy & Commerce Health Subcommittee hearing on drug pricing and the supply chain begins information gathering process, leadership says. Subcommittee Chair Burgess urges stakeholders to seek consensus on market-based solutions – or else.
But so far, OIG has declined a blanket safe harbor for proposed value-based payments, saying it still wants to consider proposals case-by-case. Discussions between the office and stakeholders are continuing, Bristol-Myers Squibb's Mike Ryan says.
Retail drug spending rose just 1.3% in 2016, following growth rates of 8.9% and 12.4% in 2015 and 2014, respectively. Moderating trend is reported just ahead of two congressional hearings on drug pricing.
US OIG's first-ever rescission means the advisory is revoked retroactively to its date of issue, which could lead to anti-kickback enforcement actions against behavior by the charity and manufacturer donors since then.
Alex Azar talks about price negotiation in Medicare Part B, whether his biopharma industry ties would influence his decisions as head of HHS, insulin price increases and importation during the first of his confirmation hearings.